To Our Dear Delegates,
As you are aware, the incidence of surgical site infection following orthopedic procedures continues to rise, threatening the ultimate success of the procedures and potentially our profession. Although research in the field continues, there is an immense gap in our knowledge related to many aspects of orthopedic infections. In fact, this issue was highlighted by the Center for Disease Control recently as they updated the SSI prevention Guidelines.
As you may be aware, the lack of evidence in many aspects of orthopedics lead us to hold the first International Consensus meeting on Periprosthetic Joint Infection in 2013. The meeting was a true success in that 204 different aspects of infections were evaluated by 350 delegates who were engaged in the Delphi process in the year leading to the consensus meeting and by personally attending the meeting in Philadelphia. The document generated by the Proceedings from the meeting has been translated to 18 languages and over 50,000 copies of the book has been distributed globally. The document was also published in many peer-reviewed journals. The document has been hailed as the bible of orthopedic infections.
We intend to hold the Second International Consensus Meeting on Prosthetic Joint Infection in Philadelphia, Pennsylvania on July 25-27, 2018. We have identified over 800 delegates who have agreed to serve in the next consensus meeting. The names of these key decision makers in Orthopaedics can be found on this website (Please see below and "Delegates 2018" tab). The delegates listed on the website have confirmed participation and are actively involved in the Delphi process that will generate the document to be voted on in our face to face meeting in July 2018.
The next meeting will be different in three aspects:
1) The next meeting will include delegates from all subspecialties of orthopedics including Foot and Ankle, Oncology, Pediatric, Shoulder and Elbow, Spine, Sports and Trauma workgroups.
2) The consensus will be conducted according to the Delphi method again. These distinguished attendees will be participating together in 18 specific workgroups in order to evaluate the available literature, extract evidence for current practices, and identify areas in need of further research. This time, however, the level of evidence related to each “recommendation” will be determined and highlighted also. In the prior consensus meeting there were numerous recommendations based on high level evidence. No published work related to orthopedic infections will be missed.
3) The meeting will allow for participation of representatives from governmental organizations, payers, and business administration including the FDA, CDC, NIH, CMS, NQF, as well as others. Although these participants will not be allowed to vote in the process, their presence is deemed to be important in developing the road map for funding, supporting, and approving technologies related to orthopedic infections in the future. Our industry Sponsors will also have a seat around the table and also be involved in the preparation of the document. Any relevant, valid data or information which could contribute to the topics being reviewed can be supplied by our Sponsors to the delegates for review and potential inclusion in the Consensus statements. This is an important part of the meeting, as some unpublished data or internal data may not be readily available to the delegates unless supplied by our Sponsors.
The main objective of the meeting is to bring together renowned experts in orthopedic infections from around the world (over 100 countries will be presented) and representative of prestigious orthopedic societies to develop a document that can be used to improve the care of our patients afflicted with musculoskeletal infections.
The success of this event will also be largely credited to our Sponsors, who we hope will lend their names and support to the event.
Thank you in advance for your willingness to participate in this important meeting and make a lasting difference in the orthopedic community.
Javad Parvizi MD, FRCS Thorsten Gehrke MD
Director, Clinical Research, Rothman Institute Director, Helios ENDO Klinik
Philadelphia, PA Hamburg, Germany
About the Delphi Process
The Delphi Process can be viewed in full by clicking here